News

The branded form of secukinumab is currently the only FDA-approved fully human biologic that directly inhibits interleukin-17A.

Abatacept is indicated across multiple inflammatory conditions, including for the treatment of adult patients with moderately to severely active rheumatoid arthritis, pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis, and active juvenile psoriatic arthritis.

Furmonertinib is in development for the treatment of advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations.

The FDA granted Wezlana with interchangeable designation after clinical trials found no clinically significant differences in safety and efficacy for the indicated conditions across multiple inflammatory diseases.

The approval of pembrolizumab (Keytruda; Merck) combined with gemcitabine and cisplatin for the treatment locally advanced unresectable or metastatic biliary tract cancer is the sixth sixth indication for the anti-PD-1 therapy for gastrointestinal cancers.

MarketsandMarkets report points to growth of over $3 billion over the next five years.

The latest people news happenings over the past month.

Effort displays the diverse perspectives, skills, and people involved with the healthcare supply chain, as industry aims to continue to push DE&I forward.

Surge acted as a precursor for the RSV-marketed drug landscape in 2023, says GlobalData.

Company to discuss acquisition and expansion of executive leadership.

New company to be publicly listed as Citius Oncology, Inc.

Parties will establish a Center of Excellence in CMIC’s NJ plant.

Logistics provider announced new hub coming to Kristiansand in February 2024.

Investment offers opportunity to expand global footprint, company says.

DataHorizzon Research anticipates an 18.1% CAGR through next decade.

Thousands of pharmacies will earn streamlined access to the OneScan Pharmacy Pro Platform, company says.

Executive comes with over 20 years of experience in the industry.

Partnership intends to indirectly boost patient medication adherence rates in the process.

Sector is anticipated to grow at a CAGR of 9.3%.

Provider acquires Healthware Group, extending its international footprint.

Northern Ireland hub undergoes $85 million expansion.

Nazaré brings together KOLs who are knowledgeable of the pharma product lifecycle.

CDMO predicts that its facilities can now potentially produce over $400 million in annual revenue.

These components take the burden off drug manufacturers to prep packaging components for sterilization, while helping to enhance the drug filling and packaging process.

The Vicenza site will run about 54,000 square feet in size.

Value is attributed to the rise in counterfeit cases and ongoing regulations surrounding anti-counterfeit packaging.

CDMO’s goal is to increase building’s aseptic manufacturing capacity.

CDMO will financially commit $10.6 million toward semi-solid and non-sterile liquid production.

Deal includes Krazati, a therapy for patients with non-small cell lung cancer.